SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-045569
Filing Date
2023-12-20
Accepted
2023-12-20 16:05:38
Documents
15
Period of Report
2023-12-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40149
2 ex99-1.htm EX-99.1 22841
3 ex99-1_001.jpg GRAPHIC 16399
  Complete submission text file 0001493152-23-045569.txt   307257

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bct-20231220.xsd EX-101.SCH 3744
5 XBRL DEFINITION FILE bct-20231220_def.xml EX-101.DEF 26582
6 XBRL LABEL FILE bct-20231220_lab.xml EX-101.LAB 36619
7 XBRL PRESENTATION FILE bct-20231220_pre.xml EX-101.PRE 25206
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5196
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 231501379
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)